Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

Core Viewpoint - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2024, indicating a mixed performance with slight revenue growth in Q4 but an overall decline for the year [1][3]. Financial Highlights - Q4 2024 total revenue is expected to be between $18.9 million and $19.1 million, reflecting a 1% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2024 total revenue is projected to be between $79.7 million and $79.9 million, representing a 2% decrease at the estimated midpoint compared to the previous year [3]. - Cash and cash equivalents as of December 31, 2024, were approximately $120 million, up from $118.6 million as of September 30, 2024 [4]. Segment Performance - Surgical Glaucoma revenue for Q4 is expected to be between $18.7 million and $18.8 million, a 9% increase at the estimated midpoint compared to Q4 2023 [5][7]. - Dry Eye revenue for Q4 is expected to be between $0.2 million and $0.3 million, a significant decrease from $1.6 million in the prior year [7]. - Full year Surgical Glaucoma revenue is expected to be between $75.8 million and $75.9 million, a 2% increase at the estimated midpoint compared to the previous year [7]. - Full year Dry Eye revenue is expected to be between $3.9 million and $4.0 million, down from $6.7 million in 2023 [7]. Cash Management - Cash generated in Q4 totaled approximately $1.4 million, a significant improvement compared to cash used of $6.4 million in the same period last year [7]. - Total cash used during the year was approximately $18.1 million, a reduction from $46.9 million in the prior year [7]. - The company aims to achieve cash flow breakeven without raising additional equity capital [7]. Strategic Outlook - The company is focused on effective cash management while investing in long-term value drivers, positioning itself well for 2025 with a strong cash position and differentiated technologies [5]. - The company anticipates continued progress towards establishing equitable reimbursed market access for its TearCare product [5].